Insulin resistance as the core defect in type 2 diabetes mellitus

American Journal of Cardiology

Volumn 90, Issue 5 SUPPL., 2002, Pages 3-10

  Goldstein, Barry J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; CYTOKINE; FATTY ACID; GLIBENCLAMIDE; GLUCOSE; INSULIN; METFORMIN; RESISTIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; DIABETES CONTROL; DISEASE ASSOCIATION; DRUG POTENCY; DYSLIPIDEMIA; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037026739     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02553-5     Document Type: Article

References (63)

1. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM a balanced overview . Diabetes Care. 15:1992;318-368.
2. Warram J.H., Martin B.C., Krolewski A.S., Soeldner J.S., Kahn C.R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 113:1990;909-915.
3. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus problems and prospects . Endocr Rev. 19:1998;477-490.
4. DeFronzo R.A. The triumvirate β-cell, muscle, liver. A collusion responsible for NIDDM . Diabetes. 37:1988;667-687.
5. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75:1995;473-486.
6. Groop L.C., Widen E., Ferrannini E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus errors of metabolism or of methods? Diabetologia. 36:1993;1326-1331.
7. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA. 286:2001;1195-1200.
8. Bloomgarden Z.T. Insulin resistance current concepts . Clin Ther. 20:1998;216-231.
9. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest. 106:2000;453-458.
10. Reaven G.M., Lithell H., Landsberg L. Mechanisms of disease hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system . N Engl J Med. 334:1996;374-381.
11. Dunaif A., Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 52:2001;401-419.
12. Franks S. Polycystic ovary syndrome. N Engl J Med. 333:1995;853-861.
13. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians. 111:1999;241-248.
14. Carey D.G., Jenkins A.B., Campbell L.V., Freund J., Chisholm D.J. Abdominal fat and insulin resistance in normal and overweight women direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM . Diabetes. 45:1996;633-638.
15. Zierath J.R., Livingston J.N., Thörne A., Bolinder J., Reynisdottir S., Lönnqvist F., Arner P. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway . Diabetologia. 41:1998;1343-1354.
16. Ferrannini E., Barrett E.J., Bevilacqua S., DeFronzo R.A. Effect of fatty acids on glucose production and utilization in man. J Clin Invest. 72:1983;1737-1747.
17. Lebovitz H.E. Type 2 diabetes an overview . Clin Chem. 45:1999;1339-1345.
18. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. i:1963;785-789.
19. Griffin M.E., Marcucci M.J., Cline G.W., Bell K., Barucci N., Lee D., Goodyear L.J., Kraegen E.W., White M.F., Shulman G.I. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes. 48:1999;1270-1274.
20. Cline G.W., Falk Petersen K., Krssak M., Shen J., Hundal R.S., Trajanoski Z., Inzucchi S., Dresner A., Rothman D.L., Shulman G.I. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med. 341:1999;240-246.
21. Dresner A., Laurent D., Marcucci M., Griffin M.E., Dufour S., Cline G.W., Slezak L.A., Andersen D.K., Hundal R.S., Rothman D.L., Falk Petersen K., Shulman G.I. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 103:1999;253-259.
22. Shuldiner A.R., Yang R., Gong D.-W. Resistin, obesity, and insulin resistance the emerging role of the adipocyte as an endocrine organ . N Engl J Med. 345:2001;1345-1346.
23. Montague C.T., O'Rahilly S. The perils of portliness causes and consequences of visceral adiposity . Diabetes. 49:2000;883-888.
24. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7:2001;941-946.
25. Hotamisligil G.S. Mechanisms of TNF-α-induced insulin resistance. Exp Clin Endocrinol Diabetes. 107:1999;119-125.
26. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 95:1995;2409-2415.
27. Matsuzawa Y., Funahashi T., Nakamura T. Molecular mechanism of metabolic syndrome X contribution of adipocytokines . Ann NY Acad Sci. 892:1999;146-154.
28. Liu L.S., Spelleken M., Röhrig K., Hauner H., Eckel J. Tumor necrosis factor-α acutely inhibits insulin signaling in human adipocytes implication of the p80 tumor necrosis factor receptor . Diabetes. 47:1998;515-522.
29. Sethi J.K., Hotamisligil G.S. The role of TNFα in adipocyte metabolism. Semin Cell Dev Biol. 10:1999;19-29.
30. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., Iwahashi H., Kuriyama H., Ouchi N., Maeda K., Nishida M., Kihara S., Sakai N., Nakajima T., Hasegawa K., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Hanafusa T., Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 20:2000;1595-1599.
31. Yang W.-S., Lee W.-J., Funahashi T., Tanaka S., Matsuzawa Y., Chao C.-L., Chen C.-L., Tai T.-Y., Chuang L.-M. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 86:2001;3815-3819.
32. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., Lazar M.A. The hormone resistin links obesity to diabetes. Nature. 409:2001;307-312.
33. Steppan C.M., Brown E.J., Wright C.M., Bhat S., Banerjee R.R., Dai C.Y., Enders G.H., Silberg D.G., Wen X., Wu G.D., Lazar M.A. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 98:2001;502-506.
34. de Courten M., Zimmet P., Hodge A., Collins V., Nicolson M., Staten M., Dowse G., Alberti K.G.M.M. Hyperleptinaemia the missing link in the metabolic syndrome? Diabet Med. 14:1997;200-208.
35. Donahue R.P., Prineas R.J., Donahue R.D., Zimmet P., Bean J.A., de Courten M., Collier G., Goldberg R.B., Skyler J.S., Schneiderman N. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. Diabetes Care. 22:1999;1092-1096.
36. Zimmet P., Boyko E.J., Collier G.R., de Courten M. Etiology of the metabolic syndrome potential role of insulin resistance, leptin resistance, and other players . Ann NY Acad Sci. 892:1999;25-44.
37. Bergman R.N. Toward physiological understanding of glucose tolerance minimal-model approach . Diabetes. 38:1989;1512-1527.
38. Kahn B.B. Type 2 diabetes when insulin secretion fails to compensate for insulin resistance . Cell. 92:1998;593-596.
39. Buchanan T.A. Pancreatic β-cell defects in gestational diabetes implications for the pathogenesis and prevention of type 2 diabetes . J Clin Endocrinol Metab. 86:2001;989-993.
40. Lebovitz H.E. Insulin secretagogues old and new . Diabetes Rev. 7:1999;139-153.
41. Pfeifer M.A., Halter J.B., Porte D. Jr. Insulin secretion in diabetes mellitus. Am J Med. 70:1981;579-588.
42. Brunzell J.D., Robertson R.P., Lerner R.L., Hazzard W.R., Ensinck J.W., Bierman E.L., Porte D. Jr. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab. 42:1976;222-229.
43. Bergstrom R.W., Wahl P.W., Leonetti D.L., Fujimoto W.Y. Association of fasting glucose levels with a delayed secretion of insulin after oral glucose in subjects with glucose intolerance. J Clin Endocrinol Metab. 71:1990;1447-1453.
44. Hofeldt F.D., Lufkin E.G., Hagler L., Block M.B., Dippé S.E., Davis J.W., Levin S.R., Forsham P.H., Herman R.H. Are abnormalities in insulin secretion responsible for reactive hypoglycemia? Diabetes. 23:1974;589-596.
45. Palmer J.P., Benson J.W., Walter R.M., Ensinck J.W. Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest. 58:1976;565-570.
46. Goldstein B.J. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes Technol Ther. 1:1999;267-275.
47. Kahn C.R., Chen L., Cohen S.E. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest. 106:2000;1305-1307.
48. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
49. Miyazaki Y., Glass L., Triplitt C., Matsuda M., Cusi K., Mahankali A., Mahankali S., Mandarino L.J., DeFronzo R.A. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia. 44:2001;2210-2219.
50. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., Nagaretani H., Matsuda M., Komuro R., Ouchi N., Kuriyama H., Hotta K., Nakamura T., Shimomura I., Matsuzawa Y. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50:2001;2094-2099.
51. Yang W.-S., Jeng C.-Y., Wu T.-J., Tanaka S., Funahashi T., Matsuzawa Y., Wang J.-P., Chen C.-L., Tai T.-Y., Chuang L.-M. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 25:2002;376-380.
52. Smith S.A., Lister C.A., Toseland C.D.N., Buckingham R.E. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab. 2:2000;363-372.
53. Akazawa S., Sun F., Ito M., Kawasaki E., Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 23:2000;1067-1071.
54. Arioglu E., Duncan-Morin J., Sebring N., Rother K.I., Gottlieb N., Lieberman J., Herion D., Kleiner D.E., Reynolds J., Premkumar A., Sumner A.E., Hoofnagle J., Reitman M.L., Taylor S.I. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 133:2000;263-274.
55. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
56. Carey DG, Cowin GJ, Galloway GJ, Dodrell DM, Richards JC, Jones NP, Biswas N. Rosiglitazone increases sensitivity and reduces factors associated withinsulin resistance in type 2 diabetics [abstract]. Diabetes Res Clin Pract 2000; 50(suppl 1):P311.
57. Finegood D.T., McArthur M.D., Kojwang D., Thomas M.J., Topp B.G., Leonard T., Buckingham R.E. β-Cell mass dynamics in Zucker diabetic fatty rats rosiglitazone prevents the rise in net cell death . Diabetes. 50:2001;1021-1029.
58. Lister C.A., Boam D., Bretherton-Watt D., Cawthorne M.A., Moore G., Loughborough S., Warrack J., Wilkinson M., Smith S.A. Rosiglitazone increases pancreatic islet area, number and insulin content, but not insulin gene expression. Diabetologia. 41:(suppl 1):1998;A169.
59. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., Tan S., Azen S.P. Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Diabetes. 50:(suppl 2):2001;A81.
60. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., Lee T.R., Fonseca V.A. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 134:2001;61-71.
61. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
62. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults findings from the Third National Health and Nutrition Examination Survey . JAMA. 287:2002;356-359.
63. Sunayama S., Watanabe Y., Daida H., Yamaguchi H. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Curr Opin Lipidol. 11:2000;397-402.